Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 2:57 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1633–1656 of 33,035 matching trials from the live ClinicalTrials.gov search.
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Assessing the Safety and Efficacy of a Novel Subcutaneous Implant Insertion Device on Healthy Adults

NCT03621787
Conditions
Healthy
Interventions
Implant insertion device
Device
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 49 Years
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Ann Arbor, Michigan
Conditions
Moderately to Severely Active Crohn Disease
Interventions
Obefazimod, Placebo
Drug · Other
Lead sponsor
Abivax S.A.
Industry
Eligibility
18 Years to 75 Years
Enrollment
212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
43
States / cities
Fairhope, Alabama • Scottsdale, Arizona • Sun City, Arizona + 40 more
Conditions
Hidradenitis Suppurativa
Interventions
CFZ533, Placebo to CFZ533, LYS006, Placebo to LYS006, MAS825, Placebo to MAS825, LOU064 25mg, LOU064 100mg, Placebo to LOU064, VAY736, Placebo to VAY736
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
248 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
8
States / cities
Clearwater, Florida • Orange Park, Florida • Tampa, Florida + 5 more
Completed Phase 2Phase 3 Interventional Results available

Vitamin D/Calcium Polyp Prevention Study

NCT00153816
Conditions
Colorectal Cancer, Polyps, Adenomas
Interventions
Calcium Carbonate, Vitamin D3, placebo
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
45 Years to 75 Years
Enrollment
2,813 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2016
U.S. locations
10
States / cities
Los Angeles, California • Denver, Colorado • Atlanta, Georgia + 7 more
Conditions
Blepharoptosis
Interventions
RVL-1201, Vehicle ophthalmic solution
Drug · Other
Lead sponsor
RVL Pharmaceuticals, Inc.
Industry
Eligibility
9 Years and older
Enrollment
234 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
35
States / cities
Phoenix, Arizona • Garden Grove, California • Mission Hills, California + 30 more
Conditions
Covid-19
Interventions
Octagam 10%, Saline Solution
Biological · Other
Lead sponsor
Octapharma
Industry
Eligibility
18 Years and older
Enrollment
207 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
15
States / cities
Sheffield, Alabama • Loma Linda, California • Newport Beach, California + 11 more
Conditions
Depression
Interventions
6(S)-5-MTHF(Deplin), Placebo
Other
Lead sponsor
George I. Papakostas
Other
Eligibility
18 Years to 65 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
6
States / cities
San Diego, California • Chicago, Illinois • Boston, Massachusetts + 3 more
Conditions
Pancreatic Cancer, Metastatic, PDAC - Pancreatic Ductal Adenocarcinoma
Interventions
E-EDV-D682, EDV-GC, Gemcitabine, Nab paclitaxel.
Drug
Lead sponsor
Engeneic Pty Limited
Industry
Eligibility
18 Years and older
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
4
States / cities
El Segundo, California • Summit, New Jersey • New York, New York + 1 more
Conditions
Primary Hyperaldosteronism
Interventions
Baxdrostat, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
15
States / cities
San Francisco, California • Farmington, Connecticut • Springfield, Illinois + 11 more
Conditions
Cardiogenic Shock
Interventions
Istaroxime, Placebo
Drug
Lead sponsor
Windtree Therapeutics
Industry
Eligibility
18 Years to 85 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
2
States / cities
Boston, Massachusetts • Portland, Oregon
Completed Phase 4 Interventional Results available

Prevention of Persistent Opioid Use in Mothers

NCT03472521
Conditions
Opioid Use, Postpartum Disorder, Chronic Pain Syndrome
Interventions
Gabapentin, Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older · Female only
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Palo Alto, California
Conditions
Crohn's Disease
Interventions
Rifaximin EIR, Placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
72
States / cities
Scottsdale, Arizona • Tucson, Arizona • Little Rock, Arkansas + 65 more
Conditions
Higher-risk Myelodysplastic Syndrome
Interventions
Lisaftoclax (APG-2575), Azacitidine Injection, Placebo
Drug · Other
Lead sponsor
Ascentage Pharma Group Inc.
Industry
Eligibility
18 Years and older
Enrollment
490 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
40
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 36 more
Conditions
Glomerular Disease, Proteinuria
Interventions
ANG-3070, Placebo
Drug
Lead sponsor
Angion Biomedica Corp
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
18
States / cities
Birmingham, Alabama • Northridge, California • Vacaville, California + 13 more
Conditions
Status Asthmaticus
Interventions
Montelukast, Placebo
Drug
Lead sponsor
Corrie Fletcher
Other
Eligibility
2 Years to 14 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
1
States / cities
Oak Lawn, Illinois
Completed Phase 2 Interventional Results available

Phase 2 Study in Adults Sensitized to Cat

NCT00689299
Conditions
Allergy
Interventions
Standardized Allergenic Extract, Cat Hair, Placebo
Biological
Lead sponsor
Antigen Laboratories, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
167 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
3
States / cities
San Diego, California • Marietta, Georgia • St Louis, Missouri
Conditions
HIV Infections
Interventions
Lamivudine/Zidovudine, Capravirine, Nelfinavir mesylate
Drug
Lead sponsor
Agouron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
46
States / cities
Tucson, Arizona • Los Angeles, California • Oakland, California + 39 more
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Effects of Smoked Marijuana on Risk Taking and Decision Making Tasks

NCT00373399
Conditions
Marijuana Use Disorder
Interventions
Inactive Marijuana (0% THC), Low THC marijuana (1.8 %THC), High THC marijuana (3.9% THC)
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
21 Years to 45 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
New York, New York
Conditions
Rheumatoid Arthritis, Arthritis, Rheumatoid, Arthritis
Interventions
Imvotamab, Placebo
Drug
Lead sponsor
IGM Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
10
States / cities
Flagstaff, Arizona • Glendale, Arizona • San Diego, California + 7 more
Completed Phase 2 Interventional Results available

A Study for Participants With Major Depression

NCT00420004
Conditions
Major Depressive Disorder
Interventions
LY2216684, Placebo, Escitalopram
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
469 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
4
States / cities
Orlando, Florida • Prairie Village, Kansas • Allentown, Pennsylvania + 1 more
Conditions
Non-small Cell Lung Cancer
Interventions
REGN2810, REGN2810/chemo/ipi, Chemotherapy, Placebo
Drug · Other
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
789 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
9
States / cities
Rancho Mirage, California • Riverside, California • Whittier, California + 6 more
Conditions
Atrial Fibrillation
Interventions
Idrabiotaparinux sodium, Warfarin, Placebo (for idrabiotaparinux), Placebo (for warfarin), Avidin, Placebo (for avidin)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
3,773 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
162
States / cities
Mobile, Alabama • Tucson, Arizona • Little Rock, Arkansas + 134 more
Conditions
Alzheimer's Disease
Interventions
Emtricitabine and tenofovir disoproxil fumarate combination, Placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
55 Years to 85 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Infection, Human Immunodeficiency Virus, HIV Infections
Interventions
GSK1265744 10 mg, GSK1265744 30 mg, GSK1265744 60 mg, Efavirenz 600 mg, Rilpivirine 25 mg, Placebo, Abacavir/Lamivudine (ABC/3TC) or Tenofovir/Emtricitabine (TDF/FTC)
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
244 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
40
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 35 more